NCT01851200 (Clinical Trial/ Brentuximab vedotin)

Study Title
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors (NCT01851200)

Trial Description
The purpose of the study is to assess the activity of brentuximab vedotin (also known as SGN-035) in refractory germ cell tumors.

This trial is sponsored by Fondazione Michelangelo. [1]

Study data

  • Condition: Germ Cell Tumors
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 9
  • Start: May 2013
  • Estimated Completion: June 2015
  • Last verified: January 2015

Study Schematic

NCT01851200 (Clinical Trial/ Brentuximab vedotin)


Last Editorial review: July 11, 2016
Information based on (NIH/NCI) and other sources.